Trial Profile
Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms LEPHT
- Sponsors Bayer; Bayer HealthCare
- 16 Dec 2023 Planned number of patients changed from 180 to 301.
- 16 Dec 2023 Planned number of patients changed from 180 to 301.
- 26 Apr 2022 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.